Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study
Background It is essential to collect a sufficient amount of tumor tissue for successful next-generation sequencing (NGS) analysis. In this study, we investigated the clinical risk factors for avoiding re-biopsy for NGS analysis (re-genome biopsy) in cases where a sufficient amount of tumor tissue could not be collected by bronchoscopy. Methods We investigated the association between clinical factors and the risk of re-genome biopsy in patients who underwent transbronchial biopsy (TBB) or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and required re-genome biopsy in cases enrolled in LC-SCRUM Asia, a prospective nationwide genome screening project in Japan. We also examined whether the frequency of re-genome biopsy decreased between the first and second halves of the enrolment period. Results Of the 572 eligible patients, 236 underwent TBB, and 134 underwent EBUS-TBNA. Twenty-four TBBs required re-genome biopsy, and multivariate analysis showed that the risk of re-genome biopsy was significantly increased in lesions where the tumor lesion was centrally located. In these cases, EBUS-TBNA should be utilized even if the lesion is a pulmonary lesion. However, it should be noted that even with EBUS-TBNA, lung field lesions are at a higher risk of re-canalization than mediastinal lymph node lesions. It was also found that even when tumor cells were detected in rapid on-site evaluation, a sufficient amount of tumor tissue was not always collected. Conclusions For centrally located pulmonary mass lesions, EBUS-TBNA, rather than TBB, can be used to obtain tumor tissues that can be analyzed by NGS..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC pulmonary medicine - 23(2023), 1 vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kunimasa, Kei [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Lung cancer diagnosis |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12890-023-02749-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053942833 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053942833 | ||
| 003 | DE-627 | ||
| 005 | 20231202064642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231202s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12890-023-02749-1 |2 doi | |
| 035 | |a (DE-627)SPR053942833 | ||
| 035 | |a (SPR)s12890-023-02749-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kunimasa, Kei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background It is essential to collect a sufficient amount of tumor tissue for successful next-generation sequencing (NGS) analysis. In this study, we investigated the clinical risk factors for avoiding re-biopsy for NGS analysis (re-genome biopsy) in cases where a sufficient amount of tumor tissue could not be collected by bronchoscopy. Methods We investigated the association between clinical factors and the risk of re-genome biopsy in patients who underwent transbronchial biopsy (TBB) or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and required re-genome biopsy in cases enrolled in LC-SCRUM Asia, a prospective nationwide genome screening project in Japan. We also examined whether the frequency of re-genome biopsy decreased between the first and second halves of the enrolment period. Results Of the 572 eligible patients, 236 underwent TBB, and 134 underwent EBUS-TBNA. Twenty-four TBBs required re-genome biopsy, and multivariate analysis showed that the risk of re-genome biopsy was significantly increased in lesions where the tumor lesion was centrally located. In these cases, EBUS-TBNA should be utilized even if the lesion is a pulmonary lesion. However, it should be noted that even with EBUS-TBNA, lung field lesions are at a higher risk of re-canalization than mediastinal lymph node lesions. It was also found that even when tumor cells were detected in rapid on-site evaluation, a sufficient amount of tumor tissue was not always collected. Conclusions For centrally located pulmonary mass lesions, EBUS-TBNA, rather than TBB, can be used to obtain tumor tissues that can be analyzed by NGS. | ||
| 650 | 4 | |a Lung cancer diagnosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Next-generation sequencing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sampling method |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NGS success rate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Re-biopsy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Matsumoto, Shingo |4 aut | |
| 700 | 1 | |a Honma, Keiichiro |4 aut | |
| 700 | 1 | |a Tamiya, Motohiro |4 aut | |
| 700 | 1 | |a Inoue, Takako |4 aut | |
| 700 | 1 | |a Kawamura, Takahisa |4 aut | |
| 700 | 1 | |a Tanada, Satoshi |4 aut | |
| 700 | 1 | |a Miyazaki, Akito |4 aut | |
| 700 | 1 | |a Kanzaki, Ryu |4 aut | |
| 700 | 1 | |a Maniwa, Tomohiro |4 aut | |
| 700 | 1 | |a Okami, Jiro |4 aut | |
| 700 | 1 | |a Matsumoto, Yuji |4 aut | |
| 700 | 1 | |a Goto, Koichi |4 aut | |
| 700 | 1 | |a Nishino, Kazumi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d London : BioMed Central, 2001 |g 23(2023), 1 vom: 01. Dez. |w (DE-627)SPR027984389 |w (DE-600)2059871-3 |x 1471-2466 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12890-023-02749-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 01 |c 12 | ||